trovafloxacin

01/01/1999 - "Trovafloxacin has shown to be effective in the treatment of infections due to Chlamydia with excellent clinical results and a good tolerance. "
08/01/1999 - "In doses ranging from 200 mg to 50 mg daily for a week and 200 mg daily for 5 days, trovafloxacin appears to be effective for chlamydial infections and is well tolerated."
08/01/1998 - "These PET results suggest that trovafloxacin will be useful in the treatment of a broad range of infections at diverse anatomic sites."
08/01/1999 - "We designed a phase-II study to determine the efficacy and safety of trovafloxacin for chlamydial infections. "
08/01/1999 - "A phase-II study of trovafloxacin for the treatment of Chlamydia trachomatis infections."

01/01/1999 - "The efficacy of trovafloxacin against Staphylococcus aureus and viridans group streptococci was investigated in vitro and in an experimental model of endocarditis. "
01/01/1999 - "Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis."
02/01/1998 - "Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis."
09/01/2000 - "Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis."
09/01/2000 - "Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis."

01/01/2000 - "The penetration of trovafloxacin (TVA), 200 mg once daily, into the airways of 17 patients with severe pneumonia was studied. "
01/01/2000 - "Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia."
02/01/1996 - "pneumophila pneumonia revealed peak serum and lung trovafloxacin levels to be 3.8 micrograms/ml and 5.0 micrograms/g, respectively, at 0.5 h and 4.2 micrograms/ml and 2.9 micrograms/g, respectively, at 1 h. "
01/01/1999 - "[Use of trovafloxacin therapy in community-acquired pneumonia]."
01/01/1999 - "Trovafloxacin is effective in the treatment of community-acquired pneumonia and nosocomial pneumonia with cure rates of > 90% and 77%, respectively. "

12/01/1998 - "These results indicate that trovafloxacin may be effective in prophylaxis and treatment of mixed infections in surgical patients."
01/01/1999 - "All these pharmacokinetic and pharmacodynamic characteristics allow to consider trovafloxacin as an interesting drug for the treatment of mixed infections or those resistant to the first line drugs."
10/01/1997 - "Because of its excellent in vitro activities against diverse bacteria, trovafloxacin has potential use as a single agent for polymicrobial infections."
11/01/2002 - "Therapy with trovafloxacin or gatifloxacin reduced the incidence of mixed infection and improved the rate of survival to 95% (trovafloxacin) or 79% (gatifloxacin), whereas the rate of survival for the controls was 5%. "
05/01/2001 - "In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model."

01/01/2001 - "coli, trovafloxacin could be beneficial in the treatment of intra-abdominal abscesses."
12/01/1998 - "Drug concentrations were greater in intra-abdominal abscesses than in serum, reflecting the good tissue penetration of trovafloxacin. "
12/01/1998 - "In these experimental models, trovafloxacin protected rats from lethal infection, reduced intra-abdominal abscess formation, and inhibited bacterial growth. "
03/01/1997 - "In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli."
01/01/2001 - "To determine the efficacy of trovafloxacin as a possible treatment for intra-abdominal abscesses, we have developed an anaerobic time-kill technique using different inocula to study the in vitro killing of Bacteroides fragilis in pure culture or in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium (VREF). "